The First of Two One-Year, Multicenter, Open-Label, Repeat-Dose, Phase II Safety Studies of PrabotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines in Adult Patients

BACKGROUND: PrabotulinumtoxinA is a 900-kDa botulinum toxin type A produced by Clostridium botulinum. OBJECTIVES: The authors sought to investigate the safety of prabotulinumtoxinA for treatment of glabellar lines. METHODS: This was a multicenter, open-label, repeat-dose, 1-year phase II safety stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman-Janette, Joely, Avelar, Rui L, Biesman, Brian S, Draelos, Zoe Diana, Gross, John E, Jones, Derek H, Lupo, Mary P, Maas, Corey S, Schlessinger, Joel, Shamban, Ava Teresa, Sundaram, Hema, Weinkle, Susan H, Young, Vernon L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Cosmetic Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8598194/
https://www.ncbi.nlm.nih.gov/pubmed/33944905
http://dx.doi.org/10.1093/asj/sjaa383

Ejemplares similares

Ejemplares similares